Use of attenuated bacteria as delivery vectors for DNA vaccines.
about
Bacterial immunotherapy of gastrointestinal tumors.Vaccines targeting the neovasculature of tumorsLactic acid bacteria--20 years exploring their potential as live vectors for mucosal vaccination.The development of a novel Mycobacterium-Escherichia coli shuttle vector system using pMyong2, a linear plasmid from Mycobacterium yongonense DSM 45126T.Genetically modified "obligate" anaerobic Salmonella typhimurium as a therapeutic strategy for neuroblastoma.Live-attenuated Salmonella as a prototype vaccine vector for passenger immunogens in humans: are we there yet?Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria.A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.Perspectives for the development of human papillomavirus vaccines and immunotherapy.Recombinant Mycobacterium smegmatis with a pMyong2 vector expressing Human Immunodeficiency Virus Type I Gag can induce enhanced virus-specific immune responses.New therapeutic avenues in ulcerative colitis: thinking out of the box.Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option.Principles of Vaccination.A new plasmid vector for DNA delivery using lactococci.Dual recombinant Lactococcus lactis for enhanced delivery of DNA vaccine reporter plasmid pPERDBY.Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.
P2860
Q34242204-98D51D0A-DF02-4213-8358-F389529358AAQ34704905-469ED8E6-699B-478B-A10D-DB40290CF38FQ35193105-9D51E5CD-0488-4584-9A87-0BE9D34968D8Q35231090-021154FE-4DC6-40E9-B169-D466E7AAE841Q35984126-DB1B6603-61D5-4134-A649-5A6445F9202AQ36837160-EC7C58F5-0B97-4655-922A-16566480673CQ37111626-BF1FE12D-1292-4C7C-B80F-A5FDD2D73F44Q37258250-48F98A9C-95D5-473E-8C02-2F954516C7CBQ37658876-5FAD4181-924F-43A0-A1A5-3AF2F6384671Q37704447-3D76B4A3-184A-4F9A-A683-A724EB18FF45Q38150670-FE681C4D-7A64-49C6-AF1A-9C9CD819D538Q38827869-DB09A199-42AD-4214-B600-11753E1EED13Q40715837-9303D6A1-3C37-46D0-B861-3327B0233468Q43176145-5FA4138F-2D5C-42B8-9150-0989F8081523Q50206607-00884002-E1CC-4C7C-AB25-820DFF752D86Q52595182-DD5525C1-7C0B-46A8-8923-65A8259527FF
P2860
Use of attenuated bacteria as delivery vectors for DNA vaccines.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Use of attenuated bacteria as delivery vectors for DNA vaccines.
@ast
Use of attenuated bacteria as delivery vectors for DNA vaccines.
@en
type
label
Use of attenuated bacteria as delivery vectors for DNA vaccines.
@ast
Use of attenuated bacteria as delivery vectors for DNA vaccines.
@en
prefLabel
Use of attenuated bacteria as delivery vectors for DNA vaccines.
@ast
Use of attenuated bacteria as delivery vectors for DNA vaccines.
@en
P2093
P2860
P356
P1476
Use of attenuated bacteria as delivery vectors for DNA vaccines.
@en
P2093
Damini Daudel
Gerald Weidinger
Simone Spreng
P2860
P304
P356
10.1586/14760584.6.1.97
P577
2007-02-01T00:00:00Z